Ask AI

Improving Outcomes With Oral SERDs in MBC: Case Challenges and Skill-Building Strategies for the Advanced Practice Provider

Video
This activity is available for 1.00 CME/CE credit(s).

Released: November 04, 2026

Expiration: May 03, 2027

See Activity Collection

Watch this on-demand webcast to discover the latest evidence and best practices for optimizing oral next-generation estrogen receptor (ER)–directed therapies in ER-positive/HER2-negative metastatic breast cancer through key clinical trial data presented alongside guidance on treatment selection, adverse event recognition and management, patient counseling, adherence, and more. Viewers will learn how to translate biomarker and efficacy data into individualized treatment decisions while helping patients navigate the practical and safety considerations of oral endocrine therapy.

Oral SERDs in MBC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with breast cancer do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Case Presentation 1



  • A.C. is a 36-yr-old woman who self-palpated a mass in the left breast

  • Imaging revealed a 3-cm mass 

  • Biopsy: grade III, invasive ductal carcinoma, ER 91%-100%, PgR 1%-10%, HER2+ FISH ratio 1.7, FNA axilla positive

  • Staging PET revealed uptake in the left breast/axilla and numerous bony lesions; biopsy T9 positive, consistent with breast primary

  • She is started on first-line treatment with abemaciclib, anastrozole, zoledronic acid, and goserelin

  • A.C. did not tolerate the abemaciclib well and self-discontinued after 2 mo

  • A.C. continues anastrozole and goserelin after stopping the abemaciclib; at follow-up, imaging confirms disease progression

Which testing approach would be most appropriate to guide her next treatment?

How confident are you in your answer?
4.

Case Presentation 2



  • J.W. is a 60-yr-old woman presenting with a new mass in her right breast

  • Diagnostic imaging revealed a 2.3-cm mass

  • Biopsy of the right breast revealed invasive ductal carcinoma, grade 2 ER/PgR 91%-100%, HER2 negative; FNA of the right axilla was positive

  • J.W. was started on ribociclib and letrozole with quarterly zoledronic acid but had radiographic progression after being on treatment for 2 yr

  • Plasma ctDNA detects an ESR1 Y537N mutation, with no actionable alteration identified in the PI3K/AKT pathway

  • She remains clinically stable without visceral crisis

Which approach best integrates these findings into her next treatment decision?

How confident are you in your answer?
5.

Case Presentation 3



  • M.R. is a 64-yr-old woman with ER+/HER2- metastatic breast cancer who is initiating camizestrant plus a CDK4/6 inhibitor

  • Her medical history includes hypertension controlled with medication; baseline ECG shows no clinically significant QTc prolongation, and she reports no preexisting visual symptoms

  • During counseling, M.R. asks what adverse effects she should watch for and whether any additional monitoring will be needed while receiving camizestrant

Which counseling and monitoring plan is most appropriate for M.R.?

How confident are you in your answer?